Showing results (151-160 of 208) with videos related to

Sort By:
Pageof 21
Blood|April 26, 2024
Obinutuzumab vs rituximab for transplant-eligible patients with mantle cell lymphomaClémentine Sarkozy, Mary Callanan, Catherine Thieblemont, et al.
Leukemia & Lymphoma|August 20, 2011
Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 10th annual conference of the European Mantle Cell Lymphoma NetworkMartin Dreyling, Hanneke C Kluin-Nelemans, Sílvia Beà, et al.
Haematologica|October 30, 2025
Marked survival gains in patients ≤ 65 years with advanced-stage mantle cell lymphoma: a pooled analysis of six randomized phase III trials, 1996-2020Linmiao Jiang, Marco Ladetto, Olivier Hermine, et al.
Hemasphere|August 7, 2024
The PI3Kδ inhibitor zandelisib on intermittent dosing in relapsed/refractory follicular lymphoma: Results from a global phase 2 studyAndrew D Zelenetz, Wojciech Jurczak, Vincent Ribrag, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 2, 2014
Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma NetworkEva Hoster, Wolfram Klapper, Olivier Hermine, et al.
Cancer|October 4, 2021
Economic burden in non-Hodgkin lymphoma survivors: The French Lymphoma Study Association SIMONAL cross-sectional studyVirginie Nerich, Christophe Guyeux, Michel Henry-Amar, et al.
Lancet (London, England)|April 16, 2016
Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trialVincent Ribrag, Serge Koscielny, Jacques Bosq, et al.
Cancer Medicine|March 3, 2023
Isatuximab in combination with cemiplimab in patients with relapsed/refractory multiple myeloma: A phase 1/2 studyAlexander Lesokhin, Richard LeBlanc, Meletios A Dimopoulos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 22, 2025
Efficacy and Safety of Capivasertib (AZD5363), a Potent, Oral Pan-AKT Inhibitor, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (CAPITAL)Daniel J Hodson, Geoffrey Shouse, Ho-Jin Shin, et al.
Leukemia & Lymphoma|April 28, 2016
Primary bone diffuse large B-cell lymphoma: a retrospective evaluation on 76 cases from French institutional and LYSA studiesSylvain Pilorge, Stephanie Harel, Vincent Ribrag, et al.
Pageof 21